Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Farhad Ravandi, Andrew H. Wei, Hartmut Döhner, Hamid Sayar, Pau Montesinos, Hervé Dombret, Dominik Selleslag, Kimmo Porkka, Jun Ho Jang, Barry Skikne, C.l. Beach, Yu Tian, Gail J. RobozClinical 2022 · DOI

BibTeX
@inproceedings{ravandi2022poster,
  author = {Farhad Ravandi and Andrew H. Wei and Hartmut Döhner and Hamid Sayar and Pau Montesinos and Hervé Dombret and Dominik Selleslag and Kimmo Porkka and Jun Ho Jang and Barry Skikne and C.L. Beach and Yu Tian and Gail J. Roboz},
  title = {{Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial}},
  booktitle = {Clinical},
  year = {2022},
  doi = {10.1016/s2152-2650(22)00743-1},
}

Loading related content...

Figure